1.
Özcan M, Cassaday RD, Zarzycka E, Vandendries E, Zhang F, Chen Y, Nieto A, Demirkan F, Montesinos P, Altuntas F. Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study. Haematologica; https://doi.org/10.3324/haematol.2024.286091 [Early view].